CAS 155648-60-5: MINODRONATE
Description:Minodronate is a bisphosphonate compound primarily used in the treatment of osteoporosis and other bone-related conditions. It functions by inhibiting osteoclast-mediated bone resorption, thereby helping to maintain or increase bone density. The chemical structure of minodronate includes a phosphorus atom bonded to two hydroxyethyl groups and a nitrogen-containing moiety, which contributes to its biological activity. It is typically administered in its sodium salt form, enhancing its solubility and bioavailability. Minodronate is characterized by its ability to bind to hydroxyapatite in bone, which allows for targeted action at sites of bone turnover. The compound is generally well-tolerated, but like other bisphosphonates, it may have side effects such as gastrointestinal discomfort or, in rare cases, osteonecrosis of the jaw. Its pharmacokinetics involve minimal systemic absorption, with most of the drug remaining in the bone matrix. Overall, minodronate represents an important therapeutic option in managing conditions associated with bone loss.
Formula:C9H12N2O7P2
InChI:InChI=1/C9H12N2O7P2/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18)
- Synonyms:
- Minodronic acid
- Ym 529
- [1-Hydroxy-2-(Imidazo[1,2-A]Pyridin-3-Yl)Ethane-1,1-Diyl]Bis(Phosphonic Acid)
- Phosphonic Acid, (1-Hydroxy-2-Imidazo(1,2-A)Pyridin-3-Ylethylidene)Bis-
![Phosphonic acid, P,P'-(1-hydroxy-2-imidazo[1,2-a]pyridin-3-ylethylidene)bis-, hydrate (1:1)](https://static.cymitquimica.com/products/IN/thumb/DA001O3F.jpg)
